Short- and long-term outcomes of patients with electrocardiographic left ventricular hypertrophy after fibrinolysis for acute myocardial infarction.

Journal Article (Journal Article;Multicenter Study)

There is conflicting evidence with regard to the value of electrocardiographic left ventricular hypertrophy (LVH) in myocardial infarction. Of 5,951 patients in the ASSENT-3 trial, 273 (5%) had LVH on baseline electrocardiograms and had significantly higher mortality rates at 30 days (11% vs 6%, p = 0.001) and 1 year (13% vs 8%, p = 0.007). After adjustment for differences in baseline parameters, LVH remained an independent predictor of 30-day (hazard ratio 2.3, 95% confidence interval 1.4 to 3.9) and 1-year (hazard ratio 1.8, 95% confidence interval 1.1 to 2.8) mortality rates. Thus, electrocardiographic LVH is a prognostic tool in identifying short- and long-term mortality rates in patients who have ST-elevation myocardial infarction and receive fibrinolysis.

Full Text

Duke Authors

Cited Authors

  • Georgescu, A; Fu, Y; Yau, C; Hassan, Q; Luchansky, J; Armstrong, PW; Wagner, G; Van de Werf, F; Goodman, SG; Assessment of the Safety and Efficacy of a New Thrombolytic Regimen Trial (ASSENT-3) Investigators,

Published Date

  • October 15, 2005

Published In

Volume / Issue

  • 96 / 8

Start / End Page

  • 1050 - 1052

PubMed ID

  • 16214436

International Standard Serial Number (ISSN)

  • 0002-9149

Digital Object Identifier (DOI)

  • 10.1016/j.amjcard.2005.06.029


  • eng

Conference Location

  • United States